Definium Therapeutics (DFTX) Liabilities and Shareholders Equity (2020 - 2026)

Definium Therapeutics (DFTX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $401.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 45.75% year-over-year to $401.3 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 15.27% YoY), while the FY2025 annual figure was $440.1 million, up 45.66% from the prior year.
• Liabilities and Shareholders Equity eased to $401.3 million in Q1 2026 per DFTX's latest filing, from $440.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $440.1 million in Q4 2025 and bottomed at $124.5 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $234.3 million across 5 years, with a median of $236.9 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity fell 26.74% — and 2024, when it surged 142.61%.
• Definium Therapeutics' Liabilities and Shareholders Equity stood at $170.0 million in 2022, then fell by 26.74% to $124.5 million in 2023, then surged by 142.61% to $302.2 million in 2024, then jumped by 45.66% to $440.1 million in 2025, then dropped by 8.82% to $401.3 million in 2026.
• Business Quant data shows DFTX's Liabilities and Shareholders Equity at $401.3 million in Q1 2026, $440.1 million in Q4 2025, and $236.9 million in Q3 2025.